| Aptamer Technology | Disease Indication | Progress* |
|---|---|---|
| BT200 | VWD type 2B | Phase 3 |
| BT200 | Hemophilia A: non-severe | Phase 3 |
| BT200 | VWD type 3 | Phase 2 |
| BT200 | VWD type 1 | Phase 2 |
| BT200 | Hemophilia A: severe | Phase 2 |
| Anti-IL-23 | Dermatology | Lead-Op |
| Anti-IL-23 | Gastroenterology | Lead-Op |
| Anti-Her3 | Oncology | Lead-Op |
| Anti-GPC3 | Oncology | Lead-Op |
| Anti-LRRC15 | Oncology | Lead-Op |
| Aptamer Technology | Disease Indication | Lead-Op | Pre-Clin Dev | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| BT200 | VWD type 2B |
| ||||
| BT200 | Hemophilia A: non-severe |
| ||||
| BT200 | VWD type 3 |
| ||||
| BT200 | VWD type 1 |
| ||||
| BT200 | Hemophilia A: severe |
| ||||
| Anti-IL-23 | Dermatology |
| ||||
| Anti-IL-23 | Gastroenterology |
| ||||
| Anti-Her3 | Oncology |
| ||||
| Anti-GPC3 | Oncology |
| ||||
| Anti-LRRC15 | Oncology |
| ||||
© 2023 Guardian Therapeutics. All rights reserved.
Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.
Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580
General Inquiries:
info@guardian-rx.com
Business Development Inquiries: businessdevelopment@guardian-rx.com